Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ligandrol

    ACTIVE PHARMA INGREDIENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 5,278Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Viking Therapeutics Presents Results from Ph 2 Study of VK2809 in NAFLD
    Viking Therapeutics Presents Results from Ph 2 Study of VK2809 in NAFLD

    13 Nov 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/viking-therapeutics-presents-results-from-phase-2-study-of-vk2809-in-patients-with-non-alcoholic-fatty-liver-disease-nafld-and-elevated-ldl-cholesterol-in-oral-late-breaker-presentation-at-the-liver-meeting-2018-300748744.html

    PR NEWSWIRE
    13 Nov 2018
    Share Share
    Viking Therapeutics Announces VK2809 Phase 2 Study Results
    Viking Therapeutics Announces VK2809 Phase 2 Study Results

    04 Oct 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/viking-therapeutics-announces-vk2809-phase-2-study-results-selected-for-oral-late-breaker-presentation-at-the-liver-meeting-2018-300724265.html

    PR NEWSWIRE
    04 Oct 2018
    Share Share
    Viking Therapeutics Announces Pricing of $175.8 Million Public Offering
    Viking Therapeutics Announces Pricing of $175.8 Million Public Offering

    20 Sep 2018

    // BIOSPACE

    https://www.biospace.com/article/releases/viking-therapeutics-announces-pricing-of-175-8-million-public-offering-of-common-stock/

    BIOSPACE
    20 Sep 2018
    Share Share